Introducing


RepathaReady helps you:

Repatha Ready™ Program | Repatha® (evolocumab)



Call 1-844-REPATHA (844-737-2842) from 9am-11pm ET, Monday-Friday and our live counselors can help your office and your patients.

RepathaReady Online is a resource now available to help optimize the process for accessing Repatha®. You and your office can:

  1. Submit insurance verification and related documents online
  2. Receive summary of benefits and other updates electronically
  3. Manage all documents and see all patients in one online location

What is RepathaReady all about?

Simplified Insurance Support

  • Personalized support with prior authorizations, insurance verifications, and more
  • Repatha® Access Specialists can come to your office to provide reimbursement assistance

Repatha® Copay Card*

  • Eligible commercially-insured patients PAY NO MORE THAN $5 for each prescription of Repatha®, regardless of income. The card may cover out of pocket costs for Repatha®, up to an annual maximum

    • Applies to deductible, co-insurance, and/or copay for Repatha®

RepathaReady Nurses

  • Registered nurses can come to your office or to your patient’s home to provide injection training
  • RepathaReady registered nurses can help your patients start and stay on Repatha®
  • One-on-one injection training and support available over the phone
  • Live injection training available for patients who need additional support

Encourage your Repatha® patients to enroll in RepathaReady to receive injection support today!



Additional Financial Assistance

Medicare Part D

  • Referrals to Independent Copay Foundations
  • Eligible patients may receive assistance to help them afford the cost of their medicine

Uninsured or Underinsured

  • Referrals to The Safety Net Foundation
  • Eligible patients may receive Repatha® at no cost

For additional information on financial assistance, please call RepathaReady 1-844-Repatha.

*Eligibility Requirements for Repatha® Copay Card: Offer is available to patients with commercial insurance and applies to deductible, coinsurance, and copay for Repatha®. This program is not open to patients receiving prescription reimbursement under any federal, state or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law.


Provided through third-party foundations (501(c)(3), tax-exempt nonprofit organizations). Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.


Up to 500% of the federal poverty level income limit.

INSURANCE SUPPORT

Coverage for Repatha® has increased

91%

of Adults Have Coverage for Repatha®
in the US1,*

Coverage for Repatha® is improving nationwide

  • ~27,000 patients have received Repatha®2,†

insurance coverage map

Additional criteria may apply. Please check with your payer regarding final coverage. The information provided is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Employer policies and the individual patient policies may vary. For the most up-to-date and complete information regarding the status of Repatha®, please contact the managed care plan directly.

Insurance Verification and Prior Authorization Assistance

  • Insurance counselors can help verify your patients' insurance benefits and determine coverage for Repatha®
  • Our RepathaReady counselors can help you initiate the insurance verification process. To get started, submit a completed Insurance Verification Form (IVF) to RepathaReady and fax it to 1‑855‑REPATHA (737‑2842)

Complete the Form (ICD-10)

Download the ICD-10 Guide

Repatha® Fulfillment

  • Once coverage has been determined for plans that allow Rx fill by specialty pharmacy, RepathaReady can send the prescription to the specialty pharmacy for mail delivery to your patient

Comprehensive Coverage Support

  • Occasionally, you may need additional insurance support, such as assistance with formulary exceptions and appeals
  • Our counselors can initiate appeals/exceptions, track coverage status, and provide sample letters to payors for your use
  • We can help determine eligibility for alternative coverage and inform patients of options

In Office One-on-One Support

  • Repatha® Access Specialists can visit your office to help you with prior authorizations and other insurance and financial assistance questions
  • RepathaReady Nurses can come to your office or to your patient's home to provide injection training

*Repatha® is on the formulary of the plans of 91% of adults with prescription drug coverage. Based on reported coverage as of March 2017. Source: Managed Markets Insights amp; Technology.


Based on IMS (NBRx) data for the period of September 11, 2015 to March 31, 2017. These data include only dispensed scripts.

REPATHA® COPAY CARD &
FINANCIAL ASSISTANCE

Repatha copay card

Repatha® Copay Card*

  • No income eligibility requirements
  • Reduces out of pocket (OOP) costs for Repatha®, including co-payments, co-insurance, and prescription deductibles
  • Pays up to an annual maximum of $5,500
  • Must be reactivated every 12 months
  • Activate a Repatha® Copay Card at www.repatha.com/copaycard or by calling 1-844-REPATHA (844-737-2842)
    Hours: 9am-11pm ET, Monday-Friday

*Eligibility Criteria—Open to patients with a Repatha® prescription who have commercial insurance. Patients may not seek reimbursement for value received from the Repatha® Copay Card from any third-party payers, including a flexible spending account or healthcare savings account. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law. If at any time patients begin receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patients will no longer be able to use this card and you must call 1-844-REPATHA to stop participation. Restrictions may appy. Offer subject to change or discontinuation without notice.

Additional Financial Assistance Options Are Available for Different Patient Types

Commercial Insurance
Repatha® Copay Card

Eligible patients

pay no more than

$5*

for each Repatha® prescription regardless of income

Medicare Part D
Referrals to Independent
Copay Foundations

Eligible patients may

receive assistance to help them afford the cost of their medicine

Uninsured or underinsured
Referrals to
The Safety Net Foundation

Eligible patients may

receive Repatha®
at no cost

up to 500% of the FPL income limit

For more information, contact RepathaReady at 1‑8‌4‌4‑R‌E‌P‌A‌T‌H‌A (1‑8‌4‌4‑7‌3‌7‑2‌8‌4‌2)

FPL = federal poverty level.

*Please see program details and eligibility criteria below. Applies to deductible, co-insurance, and/or copay for Repatha®.

Provided through third-party foundations
(501(c)(3), tax-exempt nonprofit organizations). Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.

REPATHAREADY NURSES

Registered nurses provide one-on-one support and injection training

Help your patients start on Repatha®

  • Help patients get answers about their condition and Repatha®
  • Injection training and treatment planning for patients via phone or at your patient's home
  • Registered nurses are available at 1-844-REPATHA (844-737-2842)

Help your patients stay on track with Repatha®

  • Offer continued disease and Repatha® education for patient and providers
  • If requested, ongoing reminders to help patients stay on therapy


REPATHAREADY
FOR YOUR PATIENTS

Patients can enroll in RepathaReady to get free support tools:

  • One-on-one assistance from RepathaReady Nurses
  • Starter kit
  • E-mails to help patients start and stay on therapy
  • Resources to help your patients get started with their treatment and stay on track
  • Free needle-disposal containers mailed to your patient's door

Ask your patients to call 1-844-REPATHA (844-737-2842) to enroll in RepathaReady today

References:

  1. Data on file, Amgen; 2017.
  2. Data on file, Amgen; 2016.
IMPORTANT SAFETY INFORMATION
+
See MoreClose

IMPORTANT SAFETY INFORMATION

Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to Repatha®.

Allergic reactions: Hypersensitivity reactions (e.g. rash, urticaria) have been reported in patients treated with Repatha®, including some that led to discontinuation of therapy. If signs or symptoms of serious allergic reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

Adverse reactions: The most common adverse reactions (> 5% of Repatha®-treated patients and more common than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

In a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha®-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to Repatha® treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for Repatha® and placebo, respectively).

Adverse reactions from a pool of the 52-week trial and seven 12-week trials:
Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in Repatha®-treated patients and placebo-treated patients were 0.1% and 0%, respectively.

Allergic reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common allergic reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

Neurocognitive events were reported in less than or equal to 0.2% in Repatha®-treated and placebo-treated patients.

In a pool of placebo- and active-controlled trials, as well as open-label extension studies that followed them, a total of 1,988 patients treated with Repatha® had at least one LDL‑C value < 25 mg/dL. Changes to background lipid-altering therapy were not made in response to low LDL-C values, and Repatha® dosing was not modified or interrupted on this basis. Although adverse consequences of very low LDL-C were not identified in these trials, the long-term effects of very low levels of LDL-C induced by Repatha® are unknown.

Musculoskeletal adverse reactions were reported in 14.3% of Repatha®-treated patients and 12.8% of placebo-treated patients. The most common adverse reactions that occurred at a rate greater than placebo were back pain (3.2% versus 2.9% for Repatha® and placebo, respectively), arthralgia (2.3% versus 2.2%), and myalgia (2.0% versus 1.8%).

Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is a potential for immunogenicity with Repatha®.

INDICATION

Repatha® is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C).

The effect of Repatha® on cardiovascular morbidity and mortality has not been determined.

Close
Close
Close